Compared to HER2+ and HR+ (ER+ or PR+) breast cancer, TNBC has been found to harbor more numerous and differing genomic alterations, which have more pronounced implications on mutational burden, immune activation and prognosis [19]. This evidence concerns the gene ERBB2 and breast carcinoma.